You May Also Be Interested In:
Febuxostat(Brand Name Adenuric, Uloric) is a novel non-purine selective inhibitor of xanthine oxidase currently being developed for the management of hyperuricemia in patients with gout.
It has been Approved By The European Medicines and FDA.
Hyperuricemia, elevated uric acid levels in the body, is associated with gout, a painful type of arthritis. Febuxostat, an oral, once-daily medication, is a novel non-purine, selective inhibitor of xanthine oxidase (NP-SIXO) studied for its effects on lowering levels of serum uric acid (sUA) in patients with gout.